| Literature DB >> 33114127 |
Nuria Infante-Torres1, Milagros Molina-Alarcón2, Angel Arias-Arias1, Julián Rodríguez-Almagro3, Antonio Hernández-Martínez3.
Abstract
To evaluate the association between prolonged second stage of labor and the risk of adverse neonatal outcomes with a systematic review and meta-analysis. PubMed, Scopus and EMBASE were searched using the search strategy "Labor Stage, Second" AND (length OR duration OR prolonged OR abnormal OR excessive). Observational studies that examine the relationship between prolonged second stage of labor and neonatal outcomes were selected. Prolonged second stage of labor was defined as 4 h or more in nulliparous women and 3 h or more in multiparous women. The main neonatal outcomes were 5 min Apgar score <7, admission to the Neonatal Intensive Care Unit, neonatal sepsis and neonatal death. Data collection and quality assessment were carried out independently by the three reviewers. Twelve studies were selected including 266,479 women. In nulliparous women, a second stage duration greater than 4 h increased the risk of 5 min Apgar score <7, admission to the Neonatal Intensive Care Unit and neonatal sepsis and intubation. In multiparous women, a second stage of labor greater than 3 h was related to 5 min Apgar score <7, admission to the Neonatal Intensive Care Unit, meconium staining and composite neonatal morbidity. Prolonged second stage of labor increased the risk of 5 min Apgar score <7 and admission to the Neonatal Intensive Care Unit in nulliparous and multiparous women, without increasing the risk of neonatal death. This review demonstrates that prolonged second stage of labor increases the risk of neonatal complications in nulliparous and multiparous women.Entities:
Keywords: Apgar score; Neonatal Intensive Care Unit; labor stage; meta-analysis; neonatal morbidity; newborn care; second; systematic review
Mesh:
Year: 2020 PMID: 33114127 PMCID: PMC7660349 DOI: 10.3390/ijerph17217762
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Search strategies.
| Search Strategies | ||
|---|---|---|
| Search Strategy | Database | Hits |
| “Labor Stage, Second” (Mesh) AND (length OR duration OR prolonged OR abnormal OR excessive) | PubMed | 501 |
| Scopus | 590 | |
| Embase | 777 | |
|
| ||
| Population | Nulliparous and Multiparous women | |
| Intervention | Second stage labor > 4 h in nulliparous | |
| Comparison | Second stage labor ≤ 4 h in nulliparous | |
| Outcome | Neonatal morbidity: 5 min Apgar score < 7, admission to the Neonatal Intensive Care Unit, neonatal sepsis and neonatal death. | |
Definition of variables.
| Definitions | Authors | ||||||
|---|---|---|---|---|---|---|---|
| 1995; | 2007; Cheng [ | 2009; Allen [ | 2009; Rouse [ | 2012; Bleich [ | 2017; Sandström [ | 2019; Infante [ | |
| Acidosis | NR | NR | NR | NR | NR | A pH value <7.05 and base excess <−12 in the umbilical artery. | NR |
| Birth depression | NR | NR | Delay in initiating and maintaining respirations after birth requiring resuscitation by mask or endotracheal tube for at least 3 min, a 5 min Apgar score of 3 or less, or neonatal seizures due to hypoxic-ischemic encephalopathy. | NR | NR | NR | NR |
| Intubation | NR | NR | NR | Intubation in delivery room. | NR | NR | NR |
| Heart compressions | NR | NR | NR | NR | NR | Resuscitation in delivery room with heart compressions and/or intubation. | NR |
| Advanced neonatal resuscitation | NR | NR | NR | NR | NR | NR | Type III: Oxygen therapy with positive intermittent pressure. |
| Admission to Neonatal Intensive Care Unit | Need for admission to the Neonatal Intensive Care Unit for any reason at all or with a 5 min Apgar score < 7 or arterial cord pH < 7.20. | NR | Neonatal intensive care unit admission with duration of stay longer than 24 h. | Admission to a neonatal intensive care unit for >48 h. | NR | NR | NR |
| Prolonged neonatal stay | NR | Neonatal stay >2 d for vaginal delivery and >4 d for caesarean delivery. | NR | NR | NR | NR | NR |
| Neonatal seizures | NR | NR | NR | NR | Seizures in the first 24 h of life. | NR | NR |
| Sepsis | NR | NR | Positive blood culture, septicemia or systematic infection. | NR | Positive blood culture. | NR | NR |
| Minor trauma | NR | NR | One or more of the following neonatal traumas: linear skull fracture, other fractures (clavicle, ribs, numerus, or femur), facial palsy, or cephalohematoma. | NR | NR | NR | NR |
| Major trauma | NR | NR | One or more of the following neonatal traumas: depressed skull fracture, intracranial hemorrhage, or brachial plexus palsy. | NR | NR | NR | NR |
| Composite neonatal morbidity | NR | Composite variable for 5 min Apgar <7, UA pH <7.0, UA base excess ≥12, shoulder dystocia, NICU stay, and birth trauma (which includes brachial plexus injury, facial nerve palsy, clavicular fracture, skull fracture, head laceration, and cephalohematoma defined and diagnosed by the attending pediatrician). | Composite of any of the other neonatal outcomes. | Any of the following occurrences: a 5 min Apgar score <4, an umbilical artery pH <7.0, seizures, intubation, stillbirth, neonatal death, or admission to a NICU. | NR | NR | Composite of any of the other neonatal outcomes. |
| Neonatal death | Death during the second stage of labor or in the first 28 d of life | NR | NR | NR | NR | NR | NR |
NR: not reported.
Figure 1PRISMA flow diagram of the literature reviewing process.
Characteristics of the studies analyzed.
| YEAR OF PUBLICATION | COUNTRY | STUDY DESIGN | POPULATION | DURATION OF SECOND STAGE OF LABOUR | DELIVERY MODE N (%) | USE OF EA | INCLUSION/EXCLUSION CRITERIA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–1 h | 1–2 h | 2–3 h | 3–4 h | >4 h | Spontaneous Vaginal Delivery | Operative Vaginal Delivery | Caesarean Section | |||||||
|
| Canada | Cohort study | 6041 | 2622 (43.4) | 1805 (29.9) | 927 (15.3) | 379 (6.3) | 308 (5.1) | 4942 (81.8) | 932 (15.5) | 167 (2.7) | NR |
January 1988 to December 1992. Singleton babies in cephalic presentation. BW ≥ 2500 g Fetal death diagnosed before labor and caesarean section before labor or during the first stage of labor were excluded. | |
| United States | Secondary analysis of a clinical trial | 4126 | 1901 (46.1) | 1251 | 614 (14.9) | 217 (5.2) | 143 (3.5) | 3054 (74.0) | 765 (18.5) | 307 (7.5) | 3916 (95.0) |
Nulliparous women with a singleton vertex fetus who labored spontaneously or were induced at ≥ 36 WG and who reached the second stage of labor. Exclusion criteria included maternal fever and serious medical conditions. | ||
| China | Case-control study | 307 | 206 (67.1) | 29 (9.4) | 60 (19.5) | 12 (4.0) | NR | NR | NR | NR |
NR | |||
| United States | Cohort study | 21,991 | 13,736 (62.5) | 4933 | 1833 | 1062 | 427 (2.0) | 19,326 (87.9) | 1367 (6.2) | 1298 (5.9) | 13,676 (62.2) |
Nulliparous women who reached the second stage of labor. Singleton live-born infants at ≥ 37 WG and cephalic presentation. Between January 2003 to December 2008. Fetal malformations, placenta previa and multiple gestation were excluded. | ||
| Sweden | Cohort study | 32,796 | 10,731 (32.7) | 9491 | 5856 | 3898 | 2820 (8.6) | NR | 6728 (20.5) | NR | 19,417 (59.2) |
First live singleton infant in cephalic presentation at ≥ 37 WG. From January 2008 to December 2012. Caesarean and induced deliveries and deliveries with incomplete data were excluded. | ||
| Canada | Cohort study | 1515 | NC | NC | NC | 629 (41.5) | 886 (58.5) | 615 (40.6) | 662 (43.7) | 238 (15.7) | NR |
Nulliparous women who delivered non-anomalous, term (≥ 36 WG), cephalic, live singleton neonatal weight ≥ 2500 g and who had a prolonged second stage of labor. Between January 1993 and April 2006. | ||
| Sweden | Cohort study | 42,539 | 13,558 (31.9) | 12,225 (28.7) | 7710 (18.1) | 5238 (12.3) | 3808 (9.0) | NR | NR | NR | NR |
Between January 2008 to December 2013. Nulliparous women with cephalic presentation at 37 WG or later. Elective caesarean deliveries, emergency caesareans during first stage of labor and deliveries with incomplete data were excluded (without labor partograph or notation on complete dilation of the cervix). | ||
| United States | Cohort study in a poster session | 20,029 | 16,682 (83.3) | 3347 (16.7) | 14,942 (74.6) | 3015 (15.0) | 2072 (10.4) | 20,029 (100) |
Singleton deliveries at 37 + 0 to 42 + 6 WG between January 2012 and December 2016 | |||||
|
| United States | Cohort study | 5158 | 4112 (79.7) | 550 (10.7) | 239 (4.6) | 257 (5.0) | 4480 (86.8) | 414 (8.1) | 263 (5.1) | 2274 (44.1) |
Between 1991 and 2001. All term and post-term, cephalic, live singleton births to multiparous women who had spontaneous onset of labor. Caesarean delivery before the completion of the first stage of labor, placenta previa, intrauterine fetal demise or known lethal congenital anomalies were excluded. | ||
| Spain | Cohort study | 2145 | 1589 (74.1) | 327 (15.2) | 165 (7.7) | 64 (3.0) | 2070 (96.5) | 75 (3.5) | NR | 1675 (78.1) |
Women who had given birth vaginally, with cephalic presentation and singleton babies between 2013 and 2016. Births with < 35 WG and antepartum fetal death were excluded. | |||
|
| Canada | Cohort study | 55,936 nulliparous | 38,790 (69.3) | 7832 (14.0) | 4406 (7.9) | 4908 (8.8) | 101,897 (83.8) | 15,865 (13.1) | 3734 (3.1) | 61,077 (50.3) |
Between 1988 and 2006. Liveborn singleton at or after 37 WG reaching full cervical dilatation. Deliveries that occurred before onset of labor, a major congenital anomaly, at least one previous caesarean delivery, severe pregnancy-related medical disorders or missing outcome data were excluded | ||
| 65,554 multiparous | 59,227 (90.3) | 4171 (6.3) | 1188 (1.8) | 968 (1.6) | ||||||||||
| United States | Poster session | 10,487 * | NC | NC | NC | NC | NC | NR | NR | NR | NR |
Singleton at term. | ||
NC: not calculated, NR: not reported, EA: epidural analgesia, BW: birthweight, WG: weeks gestation, *: no data on nulliparous/multiparous.
Checklist for Cohort Studies.
| . | 1995; | 2007; | 2009; | 2009; | 2011; | 2012; | 2015; | 2015; | 2017; | 2017; Ogunyemi | 2018; | 2019; |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Were the two groups similar and recruited from the same population? | Unclear * | No * | No * | Unclear * | Unclear * | Unclear * | Unclear * | Unclear * | Unclear * | Unclear * | Unclear * | Unclear * |
| 2. Were the exposures measured similarly to assign people to both exposed and unexposed groups? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 3. Was the exposure measured in a valid and reliable way? | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 4. Were confounding factors identified? | No | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes |
| 5. Were strategies to deal with confounding factors stated? | No | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | No | Yes |
| 6. Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 7. Were the outcomes measured in a valid and reliable way? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 8. Was the follow up time reported and sufficient to be long enough for outcomes to occur? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 9. Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 10. Were strategies to address incomplete follow up utilized? | NA | NA | Yes | NA | NA | NA | Yes | NA | Yes | NA | NA | Yes |
| 11. Was appropriate statistical analysis used? | Unclear | Yes | Yes | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Unclear | Yes |
NA: not applicable, *: groups recruited from the same population.
Neonatal morbidity outcomes in nulliparous women (≤4 h versus >4 h second-stage labor).
| 1 min Apgar Score <7 | 5 min Apgar Score <7 | 5 min Apgar Score <4 | 5 min Apgar Score ≤3 | Umbilical Artery | Acidosis | Birth Depression | Resuscitation at Delivery | Intubation | Heart Compressions | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | ≤4 h | >4 h | |
| 1995; Menticoglou | NR | NR | 81/5733 | 7/308 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| 2009; Allen | NR | NR | 589/51,028 | 75/4908 | NR | NR | NR | NR | NR | NR | NR | NR | 862/51,028 | 138/4908 | NR | NR | NR | NR | NR | NR | |
| 2009; Rouse | NR | NR | NR | NR | 3/3983 | 0/143 | NR | NR | 15/3983 | 1/143 | NR | NR | NR | NR | NR | NR | 19/3983 | 1/143 | NR | NR | |
| 2011; Li | 17/295 | 8/12 | 3/295 | 1/12 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| 2012; Bleich | NR | NR | NR | NR | NR | NR | 17/21,564 | 2/427 | 83/21,564 | 4/427 | NR | NR | NR | NR | 138/21,564 | 13/427 | NR | NR | NR | NR | |
| 2015; Altman | NR | NR | 188/29,976 | 39/2820 | 32/29,976 | 8/2820 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| 2015; Hunt | NR | NR | 33/629 | 44/886 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| 2017; Sandström | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 330/30,453 | 31/2976 | NR | NR | NR | NR | 58/38,731 | 13/3808 | 36/38,731 | 10/3808 | |
| 2017; Ogunyemi | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| 2018; Souter | NR | NR | 200/16,682 | 84/3347 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 851/16,682 | 248/3347 | NR | NR | NR | NR | |
| Egger Bias | 0.7861 | NC | 0.8132 | NC | NC | ||||||||||||||||
| I2 95% CI | 71.0 (2.1–85.6) | NC | NC | NC | NC | ||||||||||||||||
| Q Cochran | 0.0041 | 0.7026 | 0.8132 | <0.001 | 0.681 | ||||||||||||||||
| OR 95% CI |
|
| 2.30 (0.94–5.69) | 2.60 (0.81–8.63) * |
| ||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 1995; Menticoglou | NR | NR | NR | NR | 64/5733 | 2/308 | 5/5733 | 0/308 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2009; Allen | NR | NR | NR | NR | 3071/51,028 | 505/4908 | NR | NR | 195/51,028 | 30/4908 | NR | NR | 1311/51,028 | 162/4908 | 78/51,028 | 16/4908 | NR | NR | |||
| 2009; Rouse | NR | NR | NR | NR | 167/3983 | 14/143 | NR | NR | 6/3983 | 0/143 | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2011; Li | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2012; Bleich | NR | NR | NR | NR | 172/21,564 | 8/427 | 41/21,564 | 13/427 | 39/21,564 | 0/427 | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2015; Altman | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2015; Hunt | NR | NR | NR | NR | 12/629 | 24/886 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2017; Sandström | 58/38,731 | 10/3808 | NR | NR | 2373/38,731 | 360/3808 | 78/38,731 | 17/3808 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||
| 2017; Ogunyemi | NR | NR | 309/4215 | 37/272 | 372/4201 | 37/272 | NR | NR | NR | NR | 33/3814 | 1/250 | NR | NR | NR | NR | NR | NR | |||
| 2018; Souter | NR | NR | NR | NR | 817/16,682 | 221/3347 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 367/16,682 | 74/3347 | |||
| Egger Bias | 0.8326 | NC | NC | ||||||||||||||||||
| I2 95% CI | 48.8 (0.0–75,4) | 92.3 (78.6–95,8) | 0.0 (0–72.9) | ||||||||||||||||||
| Q Cochran | 0.0573 | <0.001 | 0.7962 | ||||||||||||||||||
| OR 95% CI |
| 4.67 (0,78–27.78) * |
| ||||||||||||||||||
|
|
|
|
|
|
| ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| 1995; Menticoglou | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 0/5733 | 0/308 | |||||||||
| 2009; Allen | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||||||||
| 2009; Rouse | 10/3983 | 1/143 | NR | NR | NR | NR | NR | NR | 98/3983 | 6/143 | NR | NR | |||||||||
| 2011; Li | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||||||||
| 2012; Bleich | NR | NR | 82/21,564 | 2/427 | NR | NR | NR | NR | NR | NR | 3/21,564 | 0/427 | |||||||||
| 2015; Altman | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||||||||
| 2015; Hunt | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||||||||
| 2017; Sandström | NR | NR | NR | NR | 75/38,731 | 22/3808 | 16/38,731 | 7/3808 | NR | NR | NR | NR | |||||||||
| 2017; Ogunyemi | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||||||||
| 2018; Souter | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |||||||||
| Egger Bias | NC | ||||||||||||||||||||
| I2 95% CI | NC | ||||||||||||||||||||
| Q Cochran | NC | ||||||||||||||||||||
| OR 95% CI | 7.21 (0.37–139.71) * | ||||||||||||||||||||
NR: not reported; NR: not calculated; CI: confidence interval; * Random effects (DerSimonian–Laird); Bold: Significant results are highlighted.
Figure 2Forest plot for 5 min Apgar Score < 7 in nulliparous women (a), admission to NICU in nulliparous women (b), 5 min Apgar Score < 7 in multiparous women (c) and (d) admission to NICU in multiparous women.
Summary of results obtained following meta-analysis of all variables studied in nulliparous women. Summary of results obtained following meta-analysis of all variables studied in multiparous women.
| Variable | Number of Studies | Number of Subjects | Egger Bias | I2 95% CI | Cochran’s Q | OR 95% CI |
|---|---|---|---|---|---|---|
| 1 min Apgar Score <7 | 1 | 307 | NC | NC | NC | NC |
| 5 min Apgar score <7 | 6 | 116,624 | 0.7861 | 71.0 (2,1–85,6) | 0.0041 | 1.65 (1.20–2.27) |
| 5 min Apgar score <4 | 2 | 36,922 | NC | NC | 0.7026 | 2.27 (1.08–4.74) |
| 5 min Apgar Score <3 | 1 | 21,991 | NC | NC | NC | NC |
| Umbilical artery pH <7 | 2 | 29,117 | 0.8132 | NC | 0.8132 | 2.30 (0.94–5.69) |
| Umbilical artery pH <7.10 | 0 | 0 | NR | NR | NR | NR |
| Umbilical artery base excess >−12 | 0 | 0 | NR | NR | NR | NR |
| Acidosis | 1 | 33,429 | NC | NC | NC | NC |
| Birth depression | 1 | 55,936 | NC | NC | NC | NC |
| Resuscitation at delivery | 2 | 42,020 | NC | NC | <0.001 | 2.60 (0.81–8.63) |
| Intubation | 2 | 46,665 | NC | NC | 0.681 | 2.19 (1.23–3.90) |
| Heart compressions | 1 | 42,539 | NC | NC | NC | NC |
| ANR | 0 | 0 | NR | NR | NR | NR |
| Meconium aspiration | 1 | 42,539 | NC | NC | NC | NC |
| Meconium-stained amniotic fluid | 1 | 4487 | NC | NC | NC | NC |
| Admission to Neonatal Intensive Care Unit | 8 | 156,650 | 0.8326 | 48.8 (0.0–75.4) | 0.0573 | 1.63 (1.44–1.84) |
| Prolonged neonatal stay | 0 | 0 | NR | NR | NR | NR |
| Neonatal seizures | 3 | 70,571 | NC | 92.3 (78.6–95.8) | <0.001 | 4.67 (0.78–27.78) |
| Neonatal sepsis | 3 | 82,053 | NC | 0.0 (0–72.9) | 0.7962 | 1.57 (1.07–2.29) |
| Birth trauma | 1 | 4064 | NC | NC | NC | NC |
| Minor trauma | 1 | 55,936 | NC | NC | NC | NC |
| Major trauma | 1 | 55,936 | NC | NC | NC | NC |
| Shoulder dystocia | 1 | 20,029 | NC | NC | NC | NC |
| Brachial plexus injury | 1 | 4126 | NC | NC | NC | NC |
| Erb’s palsy | 1 | 21,991 | NC | NC | NC | NC |
| Hypoxic ischemic encephalopathy | 1 | 42,539 | NC | NC | NC | NC |
| Hypothermia treatment | 1 | 42,539 | NC | NC | NC | NC |
| Composite neonatal morbidity | 1 | 4126 | NR | NR | NR | NR |
| Any perinatal morbidity | 0 | 0 | NR | NR | NR | NR |
| Neonatal death | 2 | 28,032 | NC | NC | NC | 7.21 (0.37–139.71) |
|
|
|
|
|
|
|
|
| 1 min Apgar Score < 7 | 0 | 0 | NR | NR | NR | NR |
| 5 min Apgar score < 7 | 3 | 72,857 | NC | 0.0 (0.0–72.9) | 0.987 | 3.67 (2.48–5.43) |
| 5 min Apgar score < 4 | 0 | 0 | NR | NR | NR | NR |
| 5 min Apgar Score ≤ 3 | 0 | 0 | NR | NR | NR | NR |
| Umbilical artery pH < 7 | 1 | 5158 | NC | NC | NC | NC |
| Umbilical artery pH < 7.10 | 1 | 1912 | NC | NC | NC | NC |
| Umbilical artery base excess > −12 | 1 | 5158 | NC | NC | NC | NC |
| Acidosis | 0 | 0 | NR | NR | NR | NR |
| Birth depression | 1 | 65,554 | NC | NC | NC | NC |
| Resuscitation at delivery | 0 | 0 | NR | NR | NR | NR |
| Intubation | 0 | 0 | NR | NR | NR | NR |
| Heart compressions | 0 | 0 | NR | NR | NR | NR |
| ANR | 1 | 2145 | NC | NC | NC | NC |
| Meconium aspiration | 0 | 0 | NR | NR | NR | NR |
| Meconium-stained amniotic fluid | 2 | 11,193 | NC | NC | 0.121 | 1.29 (1.01–1.66) |
| Admission to Neonatal Intensive Care Unit | 3 | 76,692 | NC | 0.0 (0.0–72.9) | 0.417 | 2.41 (2.02–2.88) |
| Prolonged neonatal stay | 1 | 5158 | NC | NC | NC | NC |
| Neonatal seizures | 0 | 0 | NR | NR | NR | NR |
| Neonatal sepsis | 0 | 0 | NR | NR | NR | NR |
| Birth trauma | 0 | 0 | NR | NR | NR | NR |
| Minor trauma | 1 | 65,554 | NC | NC | NC | NC |
| Major trauma | 1 | 65,554 | NC | NC | NC | NC |
| Shoulder dystocia | 1 | 5158 | NC | NC | NC | NC |
| Brachial plexus injury | 0 | 0 | NR | NR | NR | NR |
| Erb’s palsy | 0 | 0 | NR | NR | NR | NR |
| Hypoxic ischemic encephalopathy | 0 | 0 | NR | NR | NR | NR |
| Hypothermia treatment | 0 | 0 | NR | NR | NR | NR |
| Composite neonatal morbidity | 2 | 7303 | NC | NC | 0.330 | 1.97 (1.39–2.80) |
| Any perinatal morbidity | 1 | 65,554 | NC | NC | NC | NC |
| Neonatal death | 0 | 0 | NR | NR | NR | NR |
ANR: advanced neonatal resuscitation; NC: not calculated; NR: not reported.
Neonatal Morbidity Outcomes in Multiparous Women (≤3 h versus >3 h second stage of labour).
| 5 min Apgar Score <7 | Umbilical Artery pH <7.0 | Umbilical Artery pH <7.10 | Umbilical Artery Base Excess>−12 | Birth Depression | Advanced Neonatal | Meconium Amniotic Fluid or Meconium Staining | NICU Admission | Prolonged Neonatal Stay | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | ≤3 h | >3 h | ≤3 h | >3 h | ≤3 h | >3 h | ≤3 h | >3 h | >3 h | ≤3 h | ≤3 h | >3 h | ≤3 h | >3 h | ≤3 h | >3 h | ≤3 h | >3 h |
| 2007; Cheng | 60/4901 | 11/257 | 17/4901 | 1/257 | NR | NR | 31/4901 | 3/257 | NR | NR | NR | NR | 1061/4901 | 73/257 | 145/4901 | 14/257 | 445/4901 | 34/257 |
| 2009; Allen | 311/64,586 | 17/968 | NR | NR | NR | NR | NR | NR | 553/64,586 | 27/968 | NR | NR | NR | NR | 2409/64,586 | 90/968 | NR | NR |
| 2017; Ogunyemi | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 290/5759 | 12/276 | 410/5700 | 40/278 | NR | NR |
| 2019; Infante | 3/2081 | 0/64 | NR | NR | 37/1858 | 3/54 | NR | NR | NR | NR | 39/2081 | 3/64 | NR | NR | NR | NR | NR | NR |
| Egger Bias | NC | NC | NC | |||||||||||||||
| I2 95% CI | 0% (0.0%–72.9%) | NC | 0% (0.0%–72.9%) | |||||||||||||||
| Q Cochran | 0.987 | 0.121 | 0.417 | |||||||||||||||
| OR 95% CI |
|
|
| |||||||||||||||
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| 2007; Cheng | NR | NR | NR | NR | 117/4901 | 10/257 | 361/4901 | 33/257 | NR | NR | ||||||||
| 2009; Allen | 586/64,586 | 27/968 | 104/64,586 | 2/968 | NR | NR | NR | NR | 3662/64,586 | 128/968 | ||||||||
| 2017; Ogunyemi | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | ||||||||
| 2019; Infante | NR | NR | NR | NR | NR | NR | 70/2081 | 6/64 | NR | NR | ||||||||
| Egger Bias | NC | |||||||||||||||||
| I2 95% CI | NC | |||||||||||||||||
| Q Cochran | 0.330 | |||||||||||||||||
| OR 95% CI |
| |||||||||||||||||
NR: not reported; NR: not calculated; CI: confidence interval; Random effects (DerSimonian–Laird); Bold: Significant results are highlighted.